# CellAegis Devices

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellaegis-devices

- Industry: Medical Devices & Equipment
- Headquarters: Toronto, Canada
- Website: www.cellaegisdevices.com
- Total disclosed funding: $9.5M
- Latest round: Series C (Mar 14, 2017)
- Investors on record: 3

## About

CellAegis Devices Inc. develops advanced security solutions focused on encryption technologies and authentication systems, ensuring data integrity for industries like healthcare, finance, and government.CellAegis Devices Inc. is headquartered in Toronto, Canada, and specializes in producing security solutions for sensitive information. The company received its latest funding of USD 9.5 mn in a Series C round on March 14, 2017, led by CTI Life Sciences Fund along with Broadview Ventures and MaRS Discovery District. The founder's history is not documented, and no subsidiaries are mentioned.Cellaegis Devices specializes in the development and manufacturing of advanced security solutions aimed at protecting sensitive information and ensuring data integrity. Their core product offerings include a range of encryption technologies and authentication systems designed for enterprise-level applications. These products serve industries such as healthcare, finance, and government, where safeguarding confidential data is paramount. The solutions are engineered to address specific use cases, including secure data transmission, access control, and compliance with regulatory frameworks. Cellaegis Devices has strategically positioned its offerings in North America, Europe, and Asia-Pacific, catering to a diverse clientele that includes large corporations, small to medium-sized enterprises, and government agencies.Cellaegis Devices generates revenue through a combination of subscription models and direct sales, primarily engaging in B2B transactions with its clients. The company’s revenue structure typically involves clients purchasing licenses for its proprietary software solutions, which may include annual subscriptions that provide ongoing support and updates. Additionally, the firm collaborates with value-added resellers and system integrators to reach a wider market, enhancing its distribution channels. The flagship products, which are integral to the company’s revenue generation, have specific pricing plans based on the scale and scope of deployment, tailored to meet the unique needs of each client. This structured approach to transactions ensures a steady revenue stream while fostering long-term partnerships with customers across various sectors.CellAegis Devices plans to utilize the recent funding from the Series C financing to enhance its product offerings and expand into new markets. The firm is currently developing new encryption technologies set to launch over the next 12 months. Additionally, the company aims to penetrate the European and Asia-Pacific markets further by the end of 2023, leveraging its existing partnerships and distribution channels to facilitate this growth.

## Funding rounds

- Series C, Mar 14, 2017, $9.5M — CTI Life Sciences, Broadview Ventures, MaRS Discovery District

## Investors

- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series C
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series C
- MaRS Discovery District — Series C